The Rise Of Strategic Partnerships Boosting Expansion In Migraine Treatment Is Influencing The Biologics CDMO Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Biologics CDMO Market Be By 2030 Compared To Its 2026 Market Size?

The biologics CDMO market size has seen rapid expansion in recent years. It is projected to increase from $24.15 billion in 2025 to $27.56 billion in 2026, with a compound annual growth rate (CAGR) of 14.1%. The growth observed in the historic period can be attributed to the rise in biologics research, advancements in cell culture technologies, increasing prevalence of chronic diseases, growth of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics cdmo market size is projected to experience swift expansion over the upcoming years. By 2030, it is anticipated to reach $48.07 billion, demonstrating a compound annual growth rate (CAGR) of 14.9%. Factors contributing to this growth during the forecast period include a significant increase in gene and cell therapy development, the integration of automation and robotics into CDMO operations, an expansion of global biologics production capabilities, greater investment in precision medicine, and an escalating need for economical biologics. Key trends for the forecast period encompass a broadening of biologics CDMO services, an uptake in mammalian cell-based production, an escalation in the outsourcing of gene therapy manufacturing, the implementation of sophisticated bioprocessing methods, and a growing requirement for biosimilars.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Key Factors Are Affecting The Biologics CDMO Market Demand?

The escalating demand for cell and genetic therapy is projected to fuel the expansion of the biologic CDMO market moving forward. These advanced medical treatments utilize living cells or genetic material to address fundamental disease causes at the cellular or genetic level, offering potential solutions for conditions resistant to conventional pharmaceuticals. The rising demand for cell and gene therapy stems from their capacity to provide innovative treatments by targeting underlying genetic or cellular issues. Biologic CDMOs offer crucial expertise in handling living cells, viral vectors, and genetic material, ensuring the safe and efficient production of these therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thus facilitating the translation from research to clinical application. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies reached $5.9 billion in 2023, representing a substantial 38% increase from 2022. Therefore, the significant rise in demand for cell and genetic therapy is a key driver for the growth of the biologic CDMO market.

What Are The Key Segment Divisions In The Biologics CDMO Market Segment Structure?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

What Emerging Trends Are Seen In The Biologics CDMO Market?

Leading companies operating in the biologics CDMO market are developing advanced technological solutions, such as new cell lines, to improve biopharmaceutical development and manufacturing efficiency and capabilities. This technology generates therapeutic antibodies with enhanced potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, introduced GS Effex cell lines, engineered to produce antibodies that are 100% free of fucose, a sugar molecule, and exhibit increased potency without sacrificing other performance attributes. This development helps overcome immunotherapy research and development challenges concerning the requirement for antibody therapeutics to boost potency. It stands as a stable, scalable, and productive cell line, offering a solution for therapeutic development from the discovery stage through to commercial manufacturing.

Which Organizations Are Engaged In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Get The Full Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Dominates The Biologics CDMO Market By Market Share?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biologics CDMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795